Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study

Brain

Volumn 119, Issue 4, 1996, Pages 1067-1077

  Hahn, A F ^a,c   Bolton, C F ^a   Zochodne, D ^b   Feasby, T E ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Chronic demyelinating polyneuropathy; CIDP; Conduction block; Double blind trial; Immunoglobulin; Intravenous

Indexed keywords

IMMUNOGLOBULIN; PREDNISONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMYELINATING NEUROPATHY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GRIP STRENGTH; GUILLAIN BARRE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEDIAN NERVE; MOTOR NERVE CONDUCTION; MUSCLE ACTION POTENTIAL; NERVE BIOPSY; NERVE STIMULATION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; PERONEUS NERVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHOOL CHILD; TIBIAL NERVE; TIME; TREATMENT OUTCOME; ULNAR NERVE;

EID: 0029776819     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/119.4.1067     Document Type: Article

References (61)

1. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). [Review]. Neurology 1991; 41: 617-8.
2. Anderson CL. Human IgG Fc receptors. [Review]. Clin Immunol Immunopathol 1989; 53: S63-71.
3. Azulay J-P, Pouget J, Pellissier J-F, Blin O, Serratrice G. Polyradiculonévrites chroniques: 25 cas. Rev Neurol (Paris) 1992; 148: 752-61.
4. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989; 46: 878-84.
5. Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin: attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989; 84: 1974-81.
6. Berchtold P, Dale GL, Tani P, McMillan R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989; 74:2414-7.
7. Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins [published erratum appears in Ann Intern Med 1990; 112: 967] [see comments]. [Review]. Ann Intern Med 1990; 112: 278-92. Comment in: Ann Intern Med 1990; 113: 897-8.
8. Cherin P, Herson S, Wechsler B, Piette J-C, Bletry O, Coutellier A, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients [see comments]. Am J Med 1991; 91: 162-8. Comment in: Am J Med 1992; 93: 114-5.
9. Churchyard A, Day T, Grainger K, Mastaglia FL. Intravenous immunoglobulin therapy in the inflammatory neuropathies. [Review], Clin Exp Neurol 1991; 28: 168-79.
10. Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 1986; 314:1236-9.
11. Cornblath DR, Chaudhry V, Griffin JW. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol 1991; 30: 104-6.
12. Curro Dossi B, Tezzon F. High-dose intravenous gammaglobulin for chronic inflammatory demyelinating polyneuropathy. Ital J Neurol Sci 1987; 8: 321-6.
13. Dwyer JM. Manipulating the immune system with immune globulin. [Review]. N Engl J Med 1992; 326: 107-16.
14. Dyck PJ. Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy and in neuropathy associated with IgM monoclonal gammopathy of unknown significance [editorial; comment] [see comments]. Neurology 1990; 40: 327-8. Comment on: Neurology 1990; 40: 209-12, Comment on: Neurology 1990, 40: 212-4, Comment in Neurology 1990; 40: 1479.
15. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50: 621-37.
16. Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11: 136-41.
17. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986; 314: 461-5.
18. Dyck PJ, Giannini C, Lais A. Pathologic alterations of nerves. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, editors. Peripheral neuropathy, 3rd ed. Philadelphia: W.B. Saunders, 1993: 514-95.
19. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36: 838-45.
20. Faed JM, Day B, Pollock M, Taylor PK, Nukada H, Hammond-Tooke GD. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology 1989; 39: 422-5.
21. Feasby TE, Brown WF, Gilbert JJ, Hahn AF. The pathological basis of conduction block in human neuropathies. J Neurol Neurosurg Psychiatry 1985; 48: 239-44.
22. Hahn AF, Chang Y, Webster HD. Development of myelinated nerve fibers in the sixth cranial nerve of the rat: a quantitative electron microscope study. J Comp Neurol 1987; 260: 491-500.
23. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy.A double-blind, sham-controlled, cross-over study. Brain 1996; 119: 1055-66.
24. Hartung H-P, Reiners K, Toyka KV, Pollard JD. Guillain-Barré syndrome and CTDP. In: Hohlfeld R, editor. Immunology of neuromuscular disease. Dordrecht: Kluwer, 1994: 33-104.
25. Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P. Subacute idiopathic demyelinating polyradiculoneuropathy [see comments]. Arch Neurol 1992; 49: 612-6. Comment in: Arch Neurol 1994; 51: 234-6.
26. Hurez V, Kaveri SV, Kazatchkine MD. Normal polyspecific immunoglobulin G (IvIg) in the treatment of autoimmune diseases. [Review]. J Autoimmun 1993; 6: 675-81.
27. Kaveri S-V, Dietrich G, Hurez V, Kazatchkine MD. Intravenous immunoglobulins (IvIg) in the treatment of autoimmune diseases [published erratum appears in Clin Exp Immunol 1992; 88: 373]. [Review]. Clin Exp Immunol 1991; 86: 192-8.
28. Kaveri S-V, Mouthon L, Kazatchkine MD. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. [Review]. J Neurol Neurosurg Psychiatry 1994; 57 Suppl: 6-8.
29. Kimberly RP, Salmon JE, Bussel JB, Crow MK, Hilgartner MW. Modulation of mononuclear phagocyte function by intravenous γ-globulin. J Immunol 1984; 132: 745-50.
30. Levinson AI. The use of IvIg in neurological disease. In: Ballow M, editor. IvIg therapy today. Totowa (NJ): The Humana Press, 1992: 119-34.
31. Lundkvist I, van Doom PA, Vermeulen M, Brand A. Spontaneous recovery from the Guillain-Barré syndrome is associated with antiidiotypic antibodies recognizing a cross-reactive idiotype on antineuroblastoma cell line antibodies. Clin Immunol Immunopathol 1993; 67: 192-8.
32. Mathiowetz V, Weber K, Volland G, Kashman N. Reliability and validity of grip and pinch strength evaluations. J Hand Surg [Am] 1984; 9: 222-6.
33. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987; 110: 1617-30.
34. Miller KB, Schenkein DP, Wasserman RL. Safety and tolerability of an intravenous immune globulin at various concentrations in 5% dextrose injection or sterile water for injection. Clin Pharm 1992; 11: 628-31.
35. Nemni R, Amadio S, Fazio R, Galardi G, Previtali S, Comi G. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating neuropathy not responsive to other treatments. J Neurol Neurosurg Psychiatry 1994; 57 Suppl: 43-5.
36. NIH Consensus Conference. Intravenous immunoglobulin. Prevention and treatment of disease. [Review]. JAMA 1990; 264: 3189-93.
37. Pollard JD. A critical review of therapies in acute and chronic inflammatory demyelinating polyneuropathies. [Review]. Muscle Nerve 1987; 10: 214-21.
38. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992; 339: 662-4.
39. Rodnitzky RL, Goeken JA. Complications of plasma exchange in neurological patients. Arch Neurol 1982; 39: 350-4.
40. Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. [Review]. Immunol Rev 1989; 110: 135-49.
41. SAS® Institute. SAS®/STAT user's guide: version 6. 4th ed. Cary (NC): SAS® Institute, 1990.
42. Saoudi A, Hurez V, de Kozak Y, Kuhn J, Kaveri SV, Kazatchkine MD, et al. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 1993; 5: 1559-67.
43. Schifferli J, Leski M, Favre H, Imbach P, Nydegger U, Davies K. High-dose intravenous IgG treatment and renal function [see comments]. Lancet 1991; 337: 457-8. Comment in: Lancet 1991; 338: 54-5.
44. Shumak KH, Rock GA. Therapeutic plasma exchange. [Review]. N Engl J Med 1984; 310: 762-71.
45. Teasley JE, Parry GJG, Sumner AJ, Garcia C, Malamut RI, Erlemeier SA. Electrophysiologic studies in patients with chronic inflammatory demyelinating polyneuropathy treated with intravenous immune globulin [abstract]. Muscle Nerve 1990; 13: 853-4.
46. Teasley JE, Parry GJ, Sumner AJ. Chronic inflammatory demyelinating polyradiculoneuropathy in children treated with intravenous immunoglobulin [abstract]. Muscle Nerve 1991; 14: 921.
47. Thornton CA, Griggs RC. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. [Review]. Ann Neurol 1994; 35: 260-8.
48. van der Meché FGA. The Guillain-Barré syndrome: plasma exchange or immunoglobulins intravenously. [Review]. J Neurol Neurosurg Psychiatry 1994; 57 Suppl: 33-4.
49. van der Meché FGA, Schmitz PIM. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group [see comments]. N Engl J Med 1992; 326: 1123-9. Comment in: N Engl J Med 1992; 327: 816.
50. van der Meché FGA, Vermeulen M, Busch HFM. Chronic inflammatory demyelinating polyneuropathy. Conduction failure before and during immunoglobulin or plasma therapy. Brain 1989; 112; 1563-71.
51. van Doom PA. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. [Review]. J Neurol Neurosurg Psychiatry 1994; 57 Suppl: 38-42.
52. van Doom PA, Brand A, Vermeulen M. Clinical significance of antibodies against peripheral nerve tissue in inflammatory polyneuropathy. Neurology 1987; 37: 1798-802.
53. van Doom PA, Brand A, Vermeulen M. Anti-neuroblastoma cell line antibodies in inflammatory demyelinating polyneuropathy: inhibition in vitro and in vivo by IV immunoglobulin. Neurology 1988; 38: 1592-5.
54. van Doom PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study [see comments]. Neurology 1990 a; 40: 209-12.
55. van Doom PA, Rossi F, Brand A, van Lint M, Vermeulen M, Kazatchkine MD. On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1990 b; 29: 57-64.
56. van Doom PA, Vermeulen M, Brand A, Mulder PGH, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 1991; 48: 217-20.
57. Vedanarayanan VV, Kandt RS, Lewis DV Jr, DeLong GR. Chronic inflammatory demyelinating polyradiculoneuropathy of childhood: treatment with high-dose intravenous immunoglobulin. Neurology 1991; 41: 828-30.
58. Vermeulen M, van der Meché FGA, Speelman JD, Weber A, Busch HFM. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci 1985; 70: 317-26.
59. Vermeulen M, van Doom PA, Brand A, Strengers PFW, Jennekens FGI, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993; 56: 36-9.
60. Watson JDG, Gibson J, Joshua DE, Kronenberg H. Aseptic meningitis associated with high dose intravenous immunoglobulin therapy [see comments]. J Neurol Neurosurg Psychiatry 1991; 54: 275-6. Comment in J Neurol Neurosurg Psychiatry 1992; 55: 980-I, Comment in: J Neurol Neurosurg Psychiatry 1993; 56: 830-1.
61. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients [letter]. Lancet 1986; 2: 217-8.